的名字
<强烈风格= " mso-bidi-font-weight:正常;“>简介:抗凝剂由于其治疗范围狭窄，其使用范围和治疗相关风险都很广。该研究旨在评估抗凝血剂利用率，知道如何进行监测，计算每次抗凝血剂的规定的日剂量（PDD）和平均规定的每日剂量（PDD / DDD），确定每个患者抗凝血剂的潜在药物相互作用和进入平均直接成本。
<强烈风格= " mso-bidi-font-weight:正常;方法:于2019年5月- 10月对三级护理教学医院心内科住院患者进行为期6个月的前瞻性观察研究，处方中含有抗凝剂。
Results: A total of 132 patients meeting inclusion criteria were enrolled in the study. Acute Coronary Syndrome (66.67%) being the common indication, Unfractionated Heparin + Enoxaparin (45.45%) and Enoxaparin (27.3%) were the frequently prescribed anticoagulants but not in dose range as defined by WHO. International Normalized Ratio (INR), Prothrombin Time (PT), activated Partial Thromboplastin Time (aPTT) and Renal function test were performed in majority of the patient (87.9% and 94.87% respectively) and as in ACCP guideline. Of the total 65 potential drug-drug interactions identified, Heparin was involved in 52 cases. Enoxaparin was
the most expensive of all the anticoagulants with Rs 9840.76 ($86.28), the average cost of anticoagulants per patient.
Conclusion: Acute coronary syndrome was the main indication and Enoxaparin, the costliest and most frequently prescribed anticoagulant among the entire patient population. Performance of the monitoring parameters were consistent with ACCP guideline.
">
